All Oncology News

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program.

A problem for many people undergoing cancer treatment.

OncLive is pleased to announce that the Herbert Irving Comprehensive Cancer Center has joined its Strategic Alliance Partnership program. This program enables the Herbert Irving Comprehensive Cancer Center to promote its institution and faculty as leaders in oncology to a national audience of oncology professionals.

Citing concerns about the safety profile of the device, ODAC unanimously recommended against the approval of the Melblez chemosaturation system for use with melphalan hydrochloride in the treatment of patients with ocular melanoma metastasized to the liver.

A single clinical trial was deemed insufficient to support approval of tivozanib for the treatment of patients with advanced renal cell carcinoma, according to a 13-1 vote by the FDA's Oncologic Drugs Advisory Committee.

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Lambrolizumab, an investigational antibody designed to target the programmed death-1 (PD-1) pathway in patients with melanoma, received a breakthrough therapy designation from the FDA after promising results from a small single-arm study.

Few baby boomers are facing the facts about aging.

The question of whether it should be legal to patent genes has reached the US Supreme Court, and the impending decision by the highest federal court in the country could significantly transform the current research landscape.

A novel small molecule inhibitor called CH1iB may be able to block a mechanism that enables human papilloma virus to cause head and neck cancer.

The Trials in Progress series is intended to stimulate discussion about ongoing clinical trials, to promote collaboration across the oncology community.

A small study found that microwave ablation therapy reduced pain associated with bone and soft tissues by half in the majority of patients treated with the technique.

USPSTF is inviting comments on screening by primary care professionals.

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

After receiving breakthrough therapy designation from the FDA for the treatment of two B-cell malignancies earlier this year, ibrutinib has received an additional breakthrough designation.

Melanoma is on the rise in children and teenagers.

As a result of sequestration-related federal budget cuts, Medicare reimbursement has been reduced by 2% across the board, with the reduction affecting a number of services offered to cancer patients.

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

The number of cancer survivors in the US continues to rise.

The novel immunotherapy talimogene laherparepvec has become the first oncolytic virus to successfully complete a phase III trial in advanced melanoma.

The compound LDK378, a highly selective inhibitor of ALK, has been granted "Breakthrough Therapy Designation" by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer.

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.

RNs with baccalaureate degrees provide the best post-surgical care.

A money-losing proposition for most practices.

Two months after temporarily delaying a package of budget cuts and tax increases, federal lawmakers allowed the changes to automatically take effect by failing to agree on an alternative plan.

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

Using different selection criteria for screening is superior to currently recommended criteria.

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

A consensus panel issues a set of discharge warning instructions regarding colorectal surgery.